The U.S. Food and Drug Administration (U.S. FDA) has issued 11 observations to the formulation manufacturing facility of Aurobindo Pharma’s subsidiary Eugia Pharma Specialities in Hyderabad.
The observations were issued on conclusion of an inspection, by the U.S. FDA, of the facility (Unit-III) from January 27 to February 6. The The observations are procedural in nature and will be responded to within the stipulated time, Aurobindo Pharma said in a filing on Friday.
Published – February 06, 2026 10:10 pm IST
